Evidence map›Paper›PMID 33640700›Full record

ArticleRedox biology2021

Identification of proteins and cellular pathways targeted by 2-nitroimidazole hypoxic cytotoxins.

Faisal Bin Rashed, Alexandru Cezar Stoica, Dawn MacDonald, Hassan El-Saidi, Carolynne Ricardo, Bhumi Bhatt, Jack Moore, Diana Diaz-Dussan, Nirilanto Ramamonjisoa, Yvonne Mowery and 4 more

Erratum issuedOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Redox biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 13 citations in OpenAlex.

  1. First-in-human study of a novel bifunctional PET tracer [European journal of nuclear medicine and molecular imaging · 2026
    Article
  2. Pimonidazole-alkyne conjugate for sensitive detection of hypoxia by Cu-catalyzed click reaction.Analytical sciences : the international journal of the Japan Society for Analytical Chemistry · 2024
    Article
  3. Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 3 countries.

Faisal Bin RashedDepartment of Oncology, University of Alberta, Edmonton, AB, T6G2R3, Canada.
Alexandru Cezar StoicaDepartment of Oncology, University of Alberta, Edmonton, AB, T6G2R3, Canada.
Dawn MacDonaldDepartment of Oncology, University of Alberta, Edmonton, AB, T6G2R3, Canada.
Hassan El-SaidiDepartment of Oncology, University of Alberta, Edmonton, AB, T6G2R3, Canada; Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Alexandria, El Sultan Hussein St. Azarita, Alexandria, Egypt.
Carolynne RicardoDepartment of Oncology, University of Alberta, Edmonton, AB, T6G2R3, Canada.
Bhumi BhattDepartment of Laboratory Medicine & Pathology, University of Alberta, Edmonton, AB, T6G2R3, Canada.
Jack MooreAlberta Proteomics and Mass Spectrometry Facility, University of Alberta, Edmonton, AB, T6G2R3, Canada.
Diana Diaz-DussanDepartment of Chemical & Materials Engineering, University of Alberta, Edmonton, AB, T6G2R3, Canada.
Nirilanto RamamonjisoaDepartment of Oncology, University of Alberta, Edmonton, AB, T6G2R3, Canada.
Yvonne MoweryRadiation Oncology, School of Medicine, Duke University, Durham, NC, 27708, United States.
Sambasivarao DamarajuDepartment of Laboratory Medicine & Pathology, University of Alberta, Edmonton, AB, T6G2R3, Canada.
Richard FahlmanDepartment of Biochemistry, University of Alberta, Edmonton, AB, T6G2R3, Canada.
Piyush KumarDepartment of Oncology, University of Alberta, Edmonton, AB, T6G2R3, Canada. Electronic address: pkumar@ualberta.ca.
Michael WeinfeldDepartment of Oncology, University of Alberta, Edmonton, AB, T6G2R3, Canada. Electronic address: mweinfel@ualberta.ca.
University of Alberta · CADuke University · US

Funding

Women's Cancer Research ProgramP30CA014236 · NCI · DUKE UNIVERSITY · PI JOHN N. NORTON · 1985 to 2026
$174.8M
NCI NIH HHS P30 CA014236
6 · The paper itself

Abstract

Tumour hypoxia negatively impacts therapy outcomes and continues to be a major unsolved clinical problem. Nitroimidazoles are hypoxia selective compounds that become entrapped in hypoxic cells by forming drug-protein adducts. They are widely used as hypoxia diagnostics and have also shown promise as hypoxia-directed therapeutics. However, little is known about the protein targets of nitroimidazoles and the resulting effects of their modification on cancer cells. Here, we report the synthesis and applications of azidoazomycin arabinofuranoside (N

Indexed as

NitroimidazolesProteomicsCell HypoxiaChromatography, LiquidCytotoxinsHumansHypoxiaTandem Mass SpectrometryCytotoxinsNitroimidazolesClick chemistryHead and neck tumourHypoxiaNitroimidazoleProteomics

Identifiers

PMID33640700
PMCPMC7933538
OpenAlexW3131237368

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.